
    
      Subjects will receive therapy Q3W until evaluation of efficacy. The first cycle include
      cisplatin and albumin-bound paclitaxel. A combination of anti-PD-1 antibody (SHR-1210) with
      cisplatin and albumin-bound paclitaxel would be given in second and third cycles. Patients
      who have demonstrated complete or partial tumour responses （CR/PR）will receive surgery and
      receive postoperative adjuvant therapy in accordance with NCCN guideline. Patients who have
      demonstrated stable disease or progressive disease （SD/PD）will receive concurrent
      radiochemotherapy.
    
  